TFS Signs New Agreement With OmniComm to Use TrialMaster® EDC
Fort Lauderdale, FL, December 14, 2017-TFS International, a global clinical contract research organization (TFS), has signed a new three-year partnership agreement with OmniComm Systems, Inc. (OTCQX: OMCM), a leading global provider of clinical data management technology. Under the agreement, TFS will use OmniComm’s TrialMaster EDC technology to develop clinical studies in multiple TFS research sites around the world.
“Our main technology partner over recent years has been OmniComm, and we are thrilled to continue to develop studies with the TrialMaster platform with innovations such as the Protocol Deviation Module, which was recently designed at TFS. Our collaborative technological advances will assist with the management of our clinical trials and ensure new medicines are brought to market for patients,” said Ed Tumaian, vice president, Global Clinical Development at TFS International.
The strong long-term relationship between the two companies and OmniComm’s extensive knowledge of the electronic data capture (EDC) products and services that are best-suited for TFS drove the decision to sign a new agreement, according to the TFS leadership team.
Other factors include:
- Successful development of efficiencies during the database setup phase of clinical studies.
- OmniComm’s ability to personalize the EDC environment for TFS customers (e.g. tailored roles and work flows within TrialMaster, ad-hoc reports and real-time connection with other vendors).
- ï· Excellent customer service from OmniComm’s technical support team.
Since 2014, TFS has used OmniComm’s EDC technology for an increasing number of concurrent studies, involving more than 1,000 sites and 5,000 patients.
“We take great pride in our ongoing partnership with TFS International, and we are delighted TFS has chosen to continue using TrialMaster as one of its strategic EDC solutions,” said Yvonne Rollinger, Ph.D., managing director of OmniComm Europe GmbH. “To have an organization as prestigious as TFS International select TrialMaster is a testament to the quality, flexibility and scalability of both our EDC technology and our business operations.”
About TFS International
TFS International is the leading, mid-size clinical contract research organization (CRO) providing global clinical development solutions. Founded in 1996 in Sweden, TFS currently operates in over 25 countries throughout Europe and North America and employs more than 800 professionals. TFS’ core therapeutic areas of expertise are oncology, immunology, dermatology, ophthalmology and CNS. Through two business areas, TFS DevelopTM and TFS PeopleTM, TFS provides services worldwide as end-to-end solutions or tactical functional services. Please visit www.tfscro.com for more information.
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, these organizations drive efficiency in clinical development, better manage risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 5,000 clinical trials. Please visit www.omnicomm.com for more information.
Trademarks
OmniComm, TrialMaster, TrialOne and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Contact Info
Kuno van der Post
OmniComm Systems, Inc.
+1.954.473.1254
KvanderPost@omnicomm.com
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
